ES2603531T3 - Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica - Google Patents

Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica Download PDF

Info

Publication number
ES2603531T3
ES2603531T3 ES10182399.5T ES10182399T ES2603531T3 ES 2603531 T3 ES2603531 T3 ES 2603531T3 ES 10182399 T ES10182399 T ES 10182399T ES 2603531 T3 ES2603531 T3 ES 2603531T3
Authority
ES
Spain
Prior art keywords
seq
acid sequence
protein
amino acid
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES10182399.5T
Other languages
English (en)
Spanish (es)
Inventor
Gary W. Zlotnick
Leah D. Fletcher
John Farley
Liesel A. Bernfield
Robert J Zagursky
Benjamin J. Metcalf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
Wyeth Holdings LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27668840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2603531(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Holdings LLC filed Critical Wyeth Holdings LLC
Application granted granted Critical
Publication of ES2603531T3 publication Critical patent/ES2603531T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • C12N9/2411—Amylases
    • C12N9/2414—Alpha-amylase (3.2.1.1.)
    • C12N9/2417—Alpha-amylase (3.2.1.1.) from microbiological source
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
    • C12N9/2471—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/22—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Neisseriaceae (F), e.g. Acinetobacter
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
ES10182399.5T 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica Expired - Lifetime ES2603531T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32810101P 2001-10-11 2001-10-11
US328101P 2001-10-11
US40693402P 2002-08-30 2002-08-30
US406934P 2002-08-30

Publications (1)

Publication Number Publication Date
ES2603531T3 true ES2603531T3 (es) 2017-02-28

Family

ID=27668840

Family Applications (14)

Application Number Title Priority Date Filing Date
ES10182487.8T Expired - Lifetime ES2615206T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES17156888T Expired - Lifetime ES2781213T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182544.6T Expired - Lifetime ES2603532T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES02804818.9T Expired - Lifetime ES2568895T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182324.3T Expired - Lifetime ES2549764T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182364.9T Expired - Lifetime ES2609039T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182590.9T Expired - Lifetime ES2561430T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182298.9T Expired - Lifetime ES2593360T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182399.5T Expired - Lifetime ES2603531T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182345.8T Expired - Lifetime ES2549765T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10183020.6T Expired - Lifetime ES2532640T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182611.3T Expired - Lifetime ES2562811T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182437.3T Expired - Lifetime ES2532639T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182469.6T Expired - Lifetime ES2625876T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica

Family Applications Before (8)

Application Number Title Priority Date Filing Date
ES10182487.8T Expired - Lifetime ES2615206T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES17156888T Expired - Lifetime ES2781213T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182544.6T Expired - Lifetime ES2603532T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES02804818.9T Expired - Lifetime ES2568895T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182324.3T Expired - Lifetime ES2549764T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182364.9T Expired - Lifetime ES2609039T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182590.9T Expired - Lifetime ES2561430T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182298.9T Expired - Lifetime ES2593360T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica

Family Applications After (5)

Application Number Title Priority Date Filing Date
ES10182345.8T Expired - Lifetime ES2549765T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10183020.6T Expired - Lifetime ES2532640T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182611.3T Expired - Lifetime ES2562811T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182437.3T Expired - Lifetime ES2532639T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
ES10182469.6T Expired - Lifetime ES2625876T3 (es) 2001-10-11 2002-10-11 Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica

Country Status (18)

Country Link
US (13) US8101194B2 (OSRAM)
EP (14) EP2366707B1 (OSRAM)
JP (6) JP2005515771A (OSRAM)
KR (4) KR101215664B1 (OSRAM)
CN (4) CN105617372A (OSRAM)
AU (3) AU2009213040C1 (OSRAM)
BE (3) BE2017C055I2 (OSRAM)
BR (1) BRPI0212999B8 (OSRAM)
CA (5) CA2894296C (OSRAM)
DK (10) DK2341062T3 (OSRAM)
ES (14) ES2615206T3 (OSRAM)
FR (4) FR15C0056I2 (OSRAM)
IL (5) IL161052A0 (OSRAM)
LU (4) LU92786I2 (OSRAM)
MX (3) MX339524B (OSRAM)
NL (4) NL300755I2 (OSRAM)
PT (10) PT3199539T (OSRAM)
WO (1) WO2003063766A2 (OSRAM)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1093517T3 (da) 1998-05-01 2008-06-23 Novartis Vaccines & Diagnostic Neisseria-meningitidis-antigener og præparater
NZ515935A (en) 1999-05-19 2004-01-30 Chiron S Combination Neisserial compositions and vaccines for the prevention of infections due to Neisseria bacteria such as meningococcal meningitis
EP2275553B1 (en) 1999-10-29 2015-05-13 Novartis Vaccines and Diagnostics S.r.l. Neisserial antigenic peptides
CA2871789C (en) 2000-01-17 2017-04-04 Novartis Vaccines And Diagnostics S.R.L. Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins
JP4763210B2 (ja) 2000-02-28 2011-08-31 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル ナイセリアのタンパク質の異種発現
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
MXPA05003863A (es) 2002-10-11 2005-09-08 Chiron Srl Vacunas polipeptidicas para amplia proteccion contra lineas hipervirulentas de meningococos.
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
JP4827726B2 (ja) 2003-01-30 2011-11-30 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル 複数の髄膜炎菌血清群に対する注射可能ワクチン
US20070253964A1 (en) * 2003-04-16 2007-11-01 Zlotnick Gary W Novel Immunogenic Compositions for the Prevention and Treatment of Meningococcal Disease
ES2397923T3 (es) 2003-10-02 2013-03-12 Novartis Ag Vacunas líquidas para múltiples serogrupos meningocócicos
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0419408D0 (en) 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
EP2425856A1 (en) 2005-04-08 2012-03-07 Wyeth LLC Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
KR101359953B1 (ko) * 2005-06-27 2014-02-21 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
AU2013201318B2 (en) * 2005-11-25 2015-11-19 Glaxosmithkline Biologicals Sa Chimeric, hybrid and tandem polypeptides of meningococcal NMB 1870
AU2016204760A1 (en) * 2006-04-26 2016-07-28 Wyeth Llc Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AU2014268186C1 (en) * 2006-04-26 2017-12-07 Wyeth Llc Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AU2007277081B2 (en) 2006-07-27 2014-02-06 Wyeth Llc High-cell density fed-batch fermentation process for producing recombinant protein
AR064642A1 (es) * 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
NZ587382A (en) 2008-02-21 2012-01-12 Novartis Ag Meningococcal fhbp polypeptides
CA2747340A1 (en) 2008-12-17 2010-06-24 Novartis Ag Meningococcal vaccines including hemoglobin receptor
JP5668049B2 (ja) 2009-03-24 2015-02-12 ノバルティス アーゲー 髄膜炎菌ｈ因子結合タンパク質および肺炎球菌糖結合体の組み合わせ
NZ595234A (en) 2009-03-24 2013-12-20 Novartis Ag Adjuvanting meningococcal factor h binding protein
EP2443250B8 (en) 2009-06-16 2016-09-21 GlaxoSmithKline Biologicals SA High-throughput complement-mediated antibody-dependent and opsonic bactericidal assays
US8858958B2 (en) 2009-08-27 2014-10-14 Novartis Ag Adjuvant comprising aluminum, oligonucleotide and polycation
EP3017828A1 (en) 2009-08-27 2016-05-11 GlaxoSmithKline Biologicals SA Hybrid polypeptides including meningococcal fhbp sequences
CA2776004A1 (en) 2009-09-30 2011-04-07 Novartis Ag Expression of meningococcal fhbp polypeptides
WO2011051893A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
CN110845585A (zh) 2010-03-30 2020-02-28 奥克兰儿童医院及研究中心 改性的h因子结合蛋白（fhbp）及其使用方法
AU2011262346B2 (en) 2010-06-04 2014-12-11 Wyeth Llc Streptococcus pneumoniae vaccine formulations
EP2585106A1 (en) * 2010-06-25 2013-05-01 Novartis AG Combinations of meningococcal factor h binding proteins
DK2608805T4 (da) * 2010-08-23 2025-06-30 Wyeth Llc STABILE FORMULERINGER AF NEISSERIA MENINGITIDIS rLP2086 ANTIGENER
BR112013005626B1 (pt) 2010-09-10 2022-07-26 Glaxosmithkline Biologicals Sa Meningococo, processo para a preparação de uma cepa meningocócica, vesículas de membrana externa, composição farmacêutica imunogênica, e, uso de uma composição
GB201015132D0 (en) * 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
RU2546873C2 (ru) 2010-09-10 2015-04-10 УАЙТ ЭлЭлСи Нелипидизированные варианты антигенов neisseria meningitidis orf2086
WO2012117377A1 (en) 2011-03-02 2012-09-07 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
WO2012153302A1 (en) 2011-05-12 2012-11-15 Novartis Ag Antipyretics to enhance tolerability of vesicle-based vaccines
US10596246B2 (en) 2011-12-29 2020-03-24 Glaxosmithkline Biological Sa Adjuvanted combinations of meningococcal factor H binding proteins
EP2809785B1 (en) 2012-02-02 2017-11-01 GlaxoSmithKline Biologicals SA Promoters for increased protein expression in meningococcus
EP2822584A1 (en) 2012-03-08 2015-01-14 Novartis AG Combination vaccines with tlr4 agonists
US10598666B2 (en) 2012-03-08 2020-03-24 Glaxosmithkline Biologicals Sa In vitro potency assay for protein-based meningococcal vaccines
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
PE20190458A1 (es) 2012-03-09 2019-04-01 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas
WO2013186753A1 (en) 2012-06-14 2013-12-19 Novartis Ag Vaccines for serogroup x meningococcus
CA2875391A1 (en) 2012-07-27 2014-01-30 Institut National De La Sante Et De La Recherche Medicale Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
AU2013311702A1 (en) 2012-09-06 2015-02-19 Novartis Ag Combination vaccines with serogroup B meningococcus and D/T/P
WO2014136064A2 (en) 2013-03-08 2014-09-12 Pfizer Inc. Immunogenic fusion polypeptides
EP3027206A4 (en) 2013-08-02 2017-03-08 Children's Hospital & Research Center Oakland Non-naturally occurring factor h binding proteins (fhbp) and methods of use thereof
CA2923129C (en) * 2013-09-08 2020-06-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
SI3110442T1 (sl) 2014-02-28 2021-01-29 Glaxosmithkline Biologicals S.A. Modificirani meningokokni fHbp polipeptidi
EP3172224B1 (en) 2014-07-23 2022-06-29 Children's Hospital & Research Center at Oakland Factor h binding protein variants and methods of use thereof
US11031102B2 (en) 2014-11-17 2021-06-08 Alexion Pharmaceuticals, Inc. Risk evaluation and management strategy involving patient follow-ups relating to the use or discontinuation of a complement inhibitor
MX391027B (es) 2015-02-19 2025-03-21 Pfizer Composiciones de neisseria meningitidis y metodos de la misma.
EP3263695A1 (en) 2016-06-29 2018-01-03 GlaxoSmithKline Biologicals SA Immunogenic compositions
CN106434720A (zh) * 2016-08-03 2017-02-22 中国医学科学院医学生物学研究所 提高脑膜炎奈瑟菌fHBP蛋白表达的方法
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
RS65362B1 (sr) 2016-09-02 2024-04-30 Sanofi Pasteur Inc Vakcina protiv neisseria meningitidis
EP3506933A2 (en) 2016-09-02 2019-07-10 GlaxoSmithKline Biologicals SA Vaccines for neisseria gonorrhoeae
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
PE20191107A1 (es) 2017-01-31 2019-08-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos
JP6856762B2 (ja) * 2017-09-28 2021-04-14 富士フイルム株式会社 撮像装置、情報取得方法及び情報取得プログラム
JP6911136B2 (ja) 2017-09-28 2021-07-28 富士フイルム株式会社 撮像装置、情報取得方法及び情報取得プログラム
TWI687696B (zh) * 2019-06-26 2020-03-11 國立中興大學 回饋型隱藏式馬可夫模型辨識器的建立方法與基於此辨識器的辨識系統的建立方法
CN115605222A (zh) 2019-09-27 2023-01-13 辉瑞公司（Us） 脑膜炎奈瑟氏菌组合物及其方法
CN114681601B (zh) * 2020-12-31 2025-08-19 基础治疗有限公司 脑膜炎奈瑟氏球菌疫苗及其应用
MX2023009728A (es) 2021-02-19 2023-08-30 Sanofi Pasteur Inc Vacuna recombinante meningococica b.
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay
WO2023138914A1 (en) 2022-01-24 2023-07-27 Koninklijke Philips N.V. Pulse wave velocity determination using co-registration between intravascular data and extraluminal image, and associated systems, devices, and methods
GB202208089D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
GB202208093D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
TW202423477A (zh) 2022-08-03 2024-06-16 美商賽諾菲巴斯德公司 針對腦膜炎奈瑟氏菌b的含佐劑免疫原性組成物
WO2025199107A1 (en) 2024-03-19 2025-09-25 Alexion Pharmaceuticals, Inc. Risk evaluation and management strategy involving patient follow-ups relating to the use or discontinuation of a complement inhibitor
CN120227449A (zh) * 2025-05-21 2025-07-01 苏州聚微生物科技有限公司 B群脑膜炎球菌疫苗组合物及其制备方法与应用
CN120241991B (zh) * 2025-06-05 2025-12-23 北京绿竹生物技术股份有限公司 一种新型的b群流脑外膜蛋白双功能载体

Family Cites Families (248)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT280356B (de) 1968-03-06 1970-04-10 Telefonbau & Normalzeit Gmbh Schaltungsanordnung zur Steuerung des zur Zwischenspeicherung des Zeitwertes eines Signales verwendeten Kondensators eines Demodulators einer Zeitmultiplexanlage
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
CH660375A5 (it) 1983-02-08 1987-04-15 Sclavo Spa Procedimento per la produzione di proteine correlate alla tossina difterica.
JPS60500673A (ja) 1983-03-08 1985-05-09 コモンウエルス　セラム　ラボラトリ−ズ　コミツシヨン 抗原活性を有するアミノ酸配列
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4668829A (en) * 1984-07-18 1987-05-26 University Patents, Inc. Ferroelectric smectic liquid crystals
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8424757D0 (en) 1984-10-01 1984-11-07 Pasteur Institut Retroviral vector
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
FR2573436B1 (fr) 1984-11-20 1989-02-17 Pasteur Institut Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
WO1987001130A1 (en) 1985-08-15 1987-02-26 Stauffer Chemical Company Tryptophan producing microorganism
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
AU606320B2 (en) 1985-11-01 1991-02-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US5514581A (en) * 1986-11-04 1996-05-07 Protein Polymer Technologies, Inc. Functional recombinantly prepared synthetic protein polymer
US4980289A (en) 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
RU2023448C1 (ru) 1987-07-30 1994-11-30 Сентро Насьональ Де Биопрепарадос Способ получения вакцины против различных патогенных серотипов менингита нейссера группы в
JPH01144977A (ja) 1987-11-30 1989-06-07 Agency Of Ind Science & Technol 新規組換えプラスミドｐＴＰＧＩＦ２
CA1315719C (en) 1988-02-05 1993-04-06 Arthur Bank Retroviral packaging cell lines and processes of using same
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
CA1339354C (en) 1988-09-01 1997-08-26 The Whitehead Institute For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
US7118757B1 (en) * 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
US5124263A (en) 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby
DK0606921T3 (da) 1989-03-09 2000-09-04 American Cyanamid Co Fremgangsmåde til isolering af Haemophilus influenzae protein E
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
CA2039921A1 (en) 1990-04-16 1991-10-17 Xandra O. Breakefield Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
AU7906691A (en) 1990-05-23 1991-12-10 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Adeno-associated virus (aav)-based eucaryotic vectors
EP0467714A1 (en) 1990-07-19 1992-01-22 Merck & Co. Inc. The class II protein of the outer membrane of neisseria meningitidis
JPH0453645U (OSRAM) * 1990-09-12 1992-05-07
CA2091678C (en) 1990-09-25 2003-04-22 Stephen C. Inglis Viral defective vaccine produced by transcomplementing cell line
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
WO1993007897A1 (en) 1991-10-21 1993-04-29 Medimmune, Inc. Bacterial expression vectors containing dna encoding secretion signals of lipoproteins
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
WO1993015115A1 (en) * 1992-01-24 1993-08-05 Cornell Research Foundation, Inc. E. coli dna polymerase iii holoenzyme and subunits
CA2145641C (en) 1992-12-03 2008-05-27 Richard J. Gregory Pseudo-adenovirus vectors
EP0616034B1 (en) 1993-03-05 2004-10-20 Wyeth Holdings Corporation Plasmid for production of CRM protein and diphtheria toxin
EP0689603A1 (en) 1993-03-19 1996-01-03 Cantab Pharmaceuticals Research Limited Defective mutant non-retroviral virus (e.g. hsv) as vaccine
DE69423383T2 (de) 1993-05-13 2000-08-24 American Cyanamid Co., Wayne Herstellung und Verwendungen von LOS-verminderten Aussenmembran-Proteinen von Gram-negativen Kokken
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
FI951138L (fi) 1993-07-13 1995-04-13 Rhone Poulenc Rorer Sa Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa
US5439808A (en) * 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
CA2168202A1 (en) 1993-07-30 1995-03-16 Joseph Dougherty Efficient gene transfer into primary lymphocytes
FR2708622B1 (fr) 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
US5550213A (en) * 1993-12-27 1996-08-27 Rutgers, The State University Of New Jersey Inhibitors of urokinase plasminogen activator
FR2714830B1 (fr) 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2715847B1 (fr) 1994-02-08 1996-04-12 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FI98045C (fi) 1994-02-21 1997-04-10 Arto Remes Laite inkontinenssihoitoa varten
FR2716459B1 (fr) 1994-02-22 1996-05-10 Univ Paris Curie Système hôte-vecteur utilisable en thérapie génique.
WO1995026411A2 (en) 1994-03-25 1995-10-05 The Uab Research Foundation Composition and methods for creating syngeneic recombinant virus-producing cells
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
EP0753069A1 (en) 1994-04-15 1997-01-15 Targeted Genetics Corporation Gene delivery fusion proteins
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
EP0710118B1 (en) * 1994-04-20 1998-11-25 U.S. Department Of The Army Vaccine against gram-negative bacterial infections
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
GB9422096D0 (en) 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
FR2727679B1 (fr) 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
BE1008978A5 (fr) 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
AU6043396A (en) 1995-06-05 1996-12-24 University Of Alabama At Birmingham Research Foundation, The Composition and methods for creating syngeneic recombinant v irus-producing cells
JP4091112B2 (ja) * 1995-06-07 2008-05-28 コノート ラボラトリーズ インコーポレーテッド リポタンパク質の発現
FR2741358B1 (fr) 1995-11-17 1998-01-02 Centre Nat Rech Scient Production de vecteurs retroviraux par l'intermediaire de vecteurs viraux a base de virus a adn
CU22559A1 (es) * 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
US5846547A (en) 1996-01-22 1998-12-08 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US6355255B1 (en) 1998-12-07 2002-03-12 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US6048527A (en) 1996-08-27 2000-04-11 Chiron Corporation Antibodies that define unique Meningococcal B epitopes and vaccine compositions
ATE208629T1 (de) 1996-08-27 2001-11-15 Chiron Corp Neisseria meningitidis serogruppe b glykokonjugate und verfahren zu deren verwendung
US6472518B1 (en) 1996-10-24 2002-10-29 Centers For Disease Control And Prevention, As Represented By The Secretary, Department Of Health And Human Services Invasion associated genes from Neisseria meningitidis serogroup B
GB9622159D0 (en) 1996-10-24 1996-12-18 Solvay Sociutu Anonyme Polyanionic polymers as adjuvants for mucosal immunization
GB9622660D0 (en) 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
DE19723095C2 (de) 1997-06-02 2001-08-23 Siemens Ag Bildrekonstruktionsverfahren für einen Computertomographen
JP2002507985A (ja) 1997-06-30 2002-03-12 ローヌ−プーラン・ロレ・エス・アー 横紋筋に核酸を導入する改良法およびその組合せ
DE69829287T2 (de) 1997-06-30 2006-04-13 Centre National De La Recherche Scientifique (Cnrs) Verbesserung der verabreichung der nukleinsäure in zellen der plurizellulären eukaryotischen organismen und kombination zur durchführung des verfahrens
AU8730798A (en) 1997-06-30 1999-01-25 Aventis Pharma S.A. Device for optimized electrotransfer of nucleic acid vectors to tissues in vivo
PL338146A1 (en) * 1997-07-17 2000-09-25 North American Vaccine Immunogenic complex combinations consisting of meningococcal porine of b group and h. influenzae polysaccharide
JPH1144977A (ja) 1997-07-25 1999-02-16 Copyer Co Ltd 画像形成装置
PT1007546E (pt) 1997-08-27 2009-04-24 Childrens Hosp & Res Ct Oak Compostos miméticos moleculares de epítopos de meningococos do serogrupo b
ATE226599T1 (de) * 1997-08-29 2002-11-15 Dow Chemical Co Homogener gefüllter polymerverbundwerkstoff
JP4472866B2 (ja) 1997-11-06 2010-06-02 カイロン ソチエタ ア レスポンサビリタ リミタータ ナイセリア抗原
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
SG152917A1 (en) 1998-01-14 2009-06-29 Chiron Srl Neisseria meningitidis antigens
JP4290875B2 (ja) * 1998-02-03 2009-07-08 センター フォア ディズィーズ コントロール アンド プリヴェンション 組換え脂質化ＰｓａＡタンパク質、調製法および使用
GB9806456D0 (en) 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
GB9808734D0 (en) 1998-04-23 1998-06-24 Smithkline Beecham Biolog Novel compounds
GB9808932D0 (en) 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
DK1093517T3 (da) * 1998-05-01 2008-06-23 Novartis Vaccines & Diagnostic Neisseria-meningitidis-antigener og præparater
PT1741443E (pt) 1998-05-29 2014-07-31 Novartis Vaccines & Diagnostic Combinação de vacinas para a meningite b/c
MXPA01003228A (es) 1998-09-30 2003-06-24 American Cyanamid Co Holotoxina de colera mutante como un coadyuvante.
ATE274353T1 (de) * 1998-09-30 2004-09-15 Us Army Verwendung von aufgereinigtem invaplex als impfstoff für gram-negativebakterien
BR9914374A (pt) 1998-10-09 2002-09-17 Chiron Corp Sequências genÈmicas de neisseria e métodos para seu uso
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6281337B1 (en) 1998-11-12 2001-08-28 Schering Corporation Methods for conversion of protein isoforms
JP2004537954A (ja) 1999-01-15 2004-12-24 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ナイセリア・メニンギティディス・ポリペプチドｂａｓｂ０５２
WO2000043518A1 (en) 1999-01-22 2000-07-27 Smithkline Beecham Biologicals S.A. Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies
GB9902084D0 (en) * 1999-01-29 1999-03-24 Smithkline Beecham Biolog Novel compounds
EP1150712B1 (en) 1999-02-05 2008-11-05 Merck & Co., Inc. Human papilloma virus vaccine formulations
ATE279943T1 (de) 1999-02-26 2004-11-15 Chiron Srl Verbesserung der bakterizidaktivität von neisseria antigenen mit cg enthaltende oligonukleotiden
US6245568B1 (en) 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
US7115730B1 (en) 1999-04-27 2006-10-03 Chiron Srl Immunogenic detoxified mutant E. coli LT-A-toxin
NZ530640A (en) 1999-04-30 2006-06-30 Chiron S Conserved neisserial antigens
CN101033467A (zh) 1999-04-30 2007-09-12 希龙公司 奈瑟球菌基因组序列及其用法
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
NZ515935A (en) * 1999-05-19 2004-01-30 Chiron S Combination Neisserial compositions and vaccines for the prevention of infections due to Neisseria bacteria such as meningococcal meningitis
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
US7384640B1 (en) 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
EP2275553B1 (en) 1999-10-29 2015-05-13 Novartis Vaccines and Diagnostics S.r.l. Neisserial antigenic peptides
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
ATE460484T1 (de) 1999-11-29 2010-03-15 Novartis Vaccines & Diagnostic 85 kda antigen von neisseria
DK1233784T3 (da) 1999-12-02 2008-09-01 Novartis Vaccines & Diagnostic Præparater og fremgangsmåder til stabilisering af biologiske molekyler efter lyofilisering
CA2871789C (en) * 2000-01-17 2017-04-04 Novartis Vaccines And Diagnostics S.R.L. Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins
JP4763210B2 (ja) * 2000-02-28 2011-08-31 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル ナイセリアのタンパク質の異種発現
DE60100814T2 (de) 2000-06-08 2004-07-01 Intercell Biomedizinische Forschungs- Und Entwicklungs Gmbh Immunstimulierende oligodeoxynukleotide
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
YU66103A (sh) 2001-01-23 2006-05-25 Aventis Pasteur Vakcina multivalentnog konjugata meningokokalnog polisaharid-proteina
GB0103424D0 (en) * 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins
CA2441327A1 (en) 2001-03-30 2002-10-10 Geneprot, Inc. Human arginine-rich protein-related compositions
AU2002258734A1 (en) 2001-04-13 2002-10-28 Wyeth Holdings Corporation Removal of bacterial endotoxin in a protein solution by immobilized metal affinity chromatography
US7534444B2 (en) 2001-04-17 2009-05-19 Novattis Vaccines And Diagnostics, Inc. Molecular mimetics of meningococcal B epitopes which elicit functionally active antibodies
DE60234695D1 (de) 2001-06-07 2010-01-21 Univ Colorado Mutantenformen von cholera holotoxin als adjuvans
AU2002322380B2 (en) 2001-06-07 2006-11-02 Government Of The United States Of America As Represented By The Uniformed Services University Of The Health Sciences Mutant forms of cholera holotoxin as an adjuvant
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
CA2452720C (en) 2001-07-26 2012-04-17 Chiron S.R.L. Vaccines comprising aluminium adjuvants and histidine
GB0121591D0 (en) * 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
WO2003025132A2 (en) 2001-09-14 2003-03-27 Invitrogen Corporation Dna polymerases and mutants thereof
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0129007D0 (en) 2001-12-04 2002-01-23 Chiron Spa Adjuvanted antigenic meningococcal compositions
ES2318117T3 (es) 2002-03-26 2009-05-01 Novartis Vaccines And Diagnostics S.R.L. Sacaridos modificados que tienen una estabilidad mejorada en agua.
MXPA04011249A (es) 2002-05-14 2005-06-06 Chiron Srl Vacunas mucosales con adyuvante de quitosano y antigenos meningococicos.
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
AU2003239744B2 (en) 2002-05-14 2008-07-03 Novartis Vaccines And Diagnostics S.R.L. Mucosal combination vaccines for bacterial meningitis
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
GB0220198D0 (en) 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
MXPA05003863A (es) 2002-10-11 2005-09-08 Chiron Srl Vacunas polipeptidicas para amplia proteccion contra lineas hipervirulentas de meningococos.
ATE466875T1 (de) 2002-11-15 2010-05-15 Novartis Vaccines & Diagnostic Unerwartete oberflächenproteine in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
WO2004065603A2 (en) 2003-01-15 2004-08-05 Wyeth Holdings Corporation Methods for increasing neisseria protein expression
JP4827726B2 (ja) 2003-01-30 2011-11-30 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル 複数の髄膜炎菌血清群に対する注射可能ワクチン
EP1603950A2 (en) 2003-03-17 2005-12-14 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
US20070253964A1 (en) 2003-04-16 2007-11-01 Zlotnick Gary W Novel Immunogenic Compositions for the Prevention and Treatment of Meningococcal Disease
ATE437633T2 (de) 2003-06-02 2009-08-15 Novartis Vaccines & Diagnostic Immunogene zusammensetzungen auf basis von biologisch abbaubaren mikroteilchen enthaltend ein diphtherie- und ein tetanustoxoid
WO2005000345A2 (en) 2003-06-23 2005-01-06 Aventis Pasteur, Inc. Immunization method against neisseria meningitidis serogroups a and c
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
ES2397923T3 (es) 2003-10-02 2013-03-12 Novartis Ag Vacunas líquidas para múltiples serogrupos meningocócicos
BRPI0417938A (pt) 2003-12-30 2007-04-17 Wyeth Corp formulações de proteìnas hidrofóbicas em uma composição imunogênica que possui tolerabilidade aperfeiçoada
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB0408978D0 (en) 2004-04-22 2004-05-26 Chiron Srl Meningococcal fermentation for preparing conjugate vaccines
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
NZ550533A (en) 2004-04-30 2010-02-26 Novartis Vaccines & Diagnostic Meningococcal conjugate vaccination comprising N. meningitidis and diphtheria toxin
GB0410220D0 (en) 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
GB0411387D0 (en) 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
CN101014618B (zh) 2004-07-23 2013-01-02 诺华疫苗和诊断有限公司 抗原的寡聚装配多肽
GB0419408D0 (en) 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
GB0419846D0 (en) 2004-09-07 2004-10-13 Chiron Srl Vaccine adjuvants for saccharides
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
EP1855715B1 (en) 2005-01-27 2013-03-13 Children's Hospital & Research Center at Oakland Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
WO2006096701A2 (en) 2005-03-07 2006-09-14 Id Biomedical Corporation Of Quebec C.O.B. As Glaxosmithkline Biologicals North America Pharmaceutical liposomal compositions
US8062641B2 (en) 2005-05-06 2011-11-22 Novartis Ag Immunogens for meningitidis-A vaccines
KR101359953B1 (ko) 2005-06-27 2014-02-21 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
ES2443529T3 (es) 2005-09-01 2014-02-19 Novartis Vaccines And Diagnostics Gmbh Vacunación múltiple incluyendo meningococo del serogrupo C
CA2621578C (en) 2005-09-05 2014-07-22 Glaxosmithkline Biologicals S.A. Serum bactericidal assay for n. meningitidis specific antisera
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
US20080305127A1 (en) 2005-12-23 2008-12-11 Glaxosmithkline Biologicals S.A. Conjugate Vaccines
TR201807355T4 (tr) 2006-03-22 2018-06-21 Glaxosmithkline Biologicals Sa Meningokokkal konjugatlarla immünizasyon rejimleri.
US20070253985A1 (en) 2006-04-26 2007-11-01 Wyeth Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US20090123499A1 (en) 2006-06-12 2009-05-14 Nathalie Devos Vaccine
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
US8039007B2 (en) 2006-06-29 2011-10-18 J. Craig Venter Institute, Inc. Polypeptides from Neisseria meningitidis
AU2007277081B2 (en) 2006-07-27 2014-02-06 Wyeth Llc High-cell density fed-batch fermentation process for producing recombinant protein
AR064642A1 (es) * 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
WO2008149238A2 (en) 2007-06-04 2008-12-11 Novartis Ag Formulation of meningitis vaccines
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
WO2009038889A1 (en) * 2007-08-02 2009-03-26 Children's Hospital And Research Center At Oakland Fhbp- and lpxl1-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
EP2462949A3 (en) 2007-10-19 2012-09-05 Novartis AG Meningococcal vaccine formulations
NZ587382A (en) 2008-02-21 2012-01-12 Novartis Ag Meningococcal fhbp polypeptides
EP2254594B1 (en) 2008-03-05 2015-06-03 Sanofi Pasteur Process for stabilizing an adjuvant containing vaccine composition
EP2265640B1 (en) * 2008-03-10 2015-11-04 Children's Hospital & Research Center at Oakland Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use
US20100035234A1 (en) 2008-05-19 2010-02-11 Novartis Ag Vaccine assays
US9387239B2 (en) 2008-05-30 2016-07-12 U.S. Army Medical Research And Materiel Command Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof
AU2009288242A1 (en) 2008-08-27 2010-03-11 Children's Hospital & Research Center At Oakland Complement factor H-based assays for serum bactericidal activity against Neisseria meningitidis
AU2009288095A1 (en) 2008-09-03 2010-03-11 Children's Hospital & Research Center At Oakland Peptides presenting an epitope of a domain of factor H binding protein and methods of use
IT1394288B1 (it) 2008-09-12 2012-06-06 Novartis Vaccines & Diagnostic Immunogeni di proteine che legano il fattore h.
EP4104821A1 (en) 2008-10-29 2022-12-21 Ablynx N.V. Formulations of single domain antigen binding molecules
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
JP5410084B2 (ja) * 2008-12-15 2014-02-05 川上産業株式会社 梱包箱及び箱状芯材
CA2747340A1 (en) 2008-12-17 2010-06-24 Novartis Ag Meningococcal vaccines including hemoglobin receptor
NZ595234A (en) 2009-03-24 2013-12-20 Novartis Ag Adjuvanting meningococcal factor h binding protein
JP5668049B2 (ja) 2009-03-24 2015-02-12 ノバルティス アーゲー 髄膜炎菌ｈ因子結合タンパク質および肺炎球菌糖結合体の組み合わせ
WO2010127172A2 (en) 2009-04-30 2010-11-04 Children's Hospital & Research Center At Oakland Chimeric factor h binding proteins (fhbp) and methods of use
US9365885B2 (en) 2009-06-16 2016-06-14 Puiying Annie Mak High-throughput complement-mediated antibody-dependent and opsonic bactericidal assays
EP3017828A1 (en) 2009-08-27 2016-05-11 GlaxoSmithKline Biologicals SA Hybrid polypeptides including meningococcal fhbp sequences
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione
CA2776004A1 (en) 2009-09-30 2011-04-07 Novartis Ag Expression of meningococcal fhbp polypeptides
GB0917647D0 (en) 2009-10-08 2009-11-25 Glaxosmithkline Biolog Sa Expression system
JP3158225U (ja) * 2009-10-22 2010-03-25 王　文燦 折畳める物置袋
WO2011051893A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
US9173954B2 (en) 2009-12-30 2015-11-03 Glaxosmithkline Biologicals Sa Polysaccharide immunogens conjugated to E. coli carrier proteins
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
WO2011110634A1 (en) 2010-03-10 2011-09-15 Glaxosmithkline Biologicals S.A. Vaccine composition
CN102802662A (zh) 2010-03-18 2012-11-28 诺华有限公司 用于脑膜炎球菌血清组b的含佐剂疫苗
CN110845585A (zh) 2010-03-30 2020-02-28 奥克兰儿童医院及研究中心 改性的h因子结合蛋白（fhbp）及其使用方法
EP2585106A1 (en) 2010-06-25 2013-05-01 Novartis AG Combinations of meningococcal factor h binding proteins
DK2608805T4 (da) 2010-08-23 2025-06-30 Wyeth Llc STABILE FORMULERINGER AF NEISSERIA MENINGITIDIS rLP2086 ANTIGENER
EP2612148B1 (en) 2010-09-04 2019-06-12 GlaxoSmithKline Biologicals SA Bactericidal antibody assays to assess immunogenicity and potency of meningococcal capsular saccharide vaccines
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
US20120070457A1 (en) 2010-09-10 2012-03-22 J. Craig Venter Institute, Inc. Polypeptides from neisseria meningitidis
RU2546873C2 (ru) 2010-09-10 2015-04-10 УАЙТ ЭлЭлСи Нелипидизированные варианты антигенов neisseria meningitidis orf2086
BR112013005626B1 (pt) 2010-09-10 2022-07-26 Glaxosmithkline Biologicals Sa Meningococo, processo para a preparação de uma cepa meningocócica, vesículas de membrana externa, composição farmacêutica imunogênica, e, uso de uma composição
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
WO2012117377A1 (en) 2011-03-02 2012-09-07 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
WO2012134975A1 (en) 2011-03-28 2012-10-04 St. Jude Children's Research Hospital Methods and compositions employing immunogenic fusion proteins
PE20190458A1 (es) 2012-03-09 2019-04-01 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
WO2014136064A2 (en) 2013-03-08 2014-09-12 Pfizer Inc. Immunogenic fusion polypeptides
US9965924B2 (en) 2013-07-15 2018-05-08 Ahmnon D. Moskowitz Methods, systems, and apparatus for playing multi-zone 21
CA2923129C (en) 2013-09-08 2020-06-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
MX391027B (es) 2015-02-19 2025-03-21 Pfizer Composiciones de neisseria meningitidis y metodos de la misma.
PE20191107A1 (es) 2017-01-31 2019-08-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos

Also Published As

Publication number Publication date
US9132182B2 (en) 2015-09-15
KR20040066793A (ko) 2004-07-27
IL245956B (en) 2019-02-28
US9107873B2 (en) 2015-08-18
CA2894296C (en) 2018-05-01
JP5923070B2 (ja) 2016-05-24
US20130259889A1 (en) 2013-10-03
CA2463476C (en) 2017-09-12
KR20110117726A (ko) 2011-10-27
LUC00040I1 (OSRAM) 2017-10-16
US10300122B2 (en) 2019-05-28
JP2017025061A (ja) 2017-02-02
DK2371836T3 (en) 2017-02-20
CA2918207C (en) 2016-10-18
EP2351767A2 (en) 2011-08-03
KR20100028657A (ko) 2010-03-12
CN102836426B (zh) 2016-09-28
DK2343308T3 (en) 2015-03-30
EP2348036A2 (en) 2011-07-27
EP2351767B1 (en) 2015-08-26
EP2343308A2 (en) 2011-07-13
AU2009213040A1 (en) 2009-10-08
US20120034261A1 (en) 2012-02-09
US20170173140A1 (en) 2017-06-22
US20120301496A1 (en) 2012-11-29
FR17C1043I1 (OSRAM) 2017-12-22
ES2781213T3 (es) 2020-08-31
ES2568895T3 (es) 2016-05-05
ES2561430T3 (es) 2016-02-26
PT3199539T (pt) 2020-04-01
EP2348036A3 (en) 2011-08-03
DK3199539T3 (da) 2020-04-27
AU2012202916B2 (en) 2013-08-01
CA2939781A1 (en) 2003-08-07
BRPI0212999B8 (pt) 2021-07-27
DK2332961T3 (en) 2016-10-03
CA2849427C (en) 2016-10-04
PT2348036E (pt) 2016-03-09
NL300897I2 (nl) 2018-04-06
ES2562811T3 (es) 2016-03-08
NL300899I1 (nl) 2017-10-20
CN102755631A (zh) 2012-10-31
EP2366707B1 (en) 2016-09-21
NL300755I2 (nl) 2025-11-25
JP5976880B2 (ja) 2016-08-24
CN1578785B (zh) 2013-03-13
KR101099916B1 (ko) 2011-12-28
CN102836426A (zh) 2012-12-26
EP2371836A1 (en) 2011-10-05
IL233545A (en) 2017-10-31
EP2332961A3 (en) 2011-07-27
WO2003063766A2 (en) 2003-08-07
HK1178800A1 (zh) 2013-09-19
CA2849427A1 (en) 2003-08-07
US20120201844A1 (en) 2012-08-09
FR15C0056I2 (fr) 2016-06-03
JP5997400B2 (ja) 2016-09-28
IL245955B (en) 2018-01-31
IL245955A0 (en) 2016-07-31
CA2463476A1 (en) 2003-08-07
FR17C1042I1 (OSRAM) 2017-12-22
ES2532639T3 (es) 2015-03-30
LUC00042I1 (OSRAM) 2017-10-16
KR101068318B1 (ko) 2011-09-28
KR101215664B1 (ko) 2012-12-26
HK1178429A1 (zh) 2013-09-13
ES2549765T3 (es) 2015-11-02
US20120308595A1 (en) 2012-12-06
US20150335724A1 (en) 2015-11-26
US20200138933A1 (en) 2020-05-07
IL233545A0 (en) 2014-08-31
CN105617372A (zh) 2016-06-01
CA2918207A1 (en) 2003-08-07
MX339524B (es) 2016-05-30
EP2371837A1 (en) 2011-10-05
NL300896I2 (nl) 2018-04-06
DK2371838T3 (en) 2016-02-22
EP2341062A2 (en) 2011-07-06
JP2005515771A (ja) 2005-06-02
US20190151431A1 (en) 2019-05-23
EP2332961B1 (en) 2016-07-27
EP2348036B1 (en) 2015-12-16
IL245956A0 (en) 2016-07-31
CN102755631B (zh) 2015-11-25
NL300899I2 (nl) 2018-04-06
FR15C0056I1 (OSRAM) 2015-09-11
BRPI0212999B1 (pt) 2020-04-28
US8563007B1 (en) 2013-10-22
EP2371837B1 (en) 2016-09-21
AU2012202916C1 (en) 2017-06-08
EP2348035B1 (en) 2015-02-18
EP2341063A3 (en) 2011-09-14
DK2341063T3 (en) 2015-10-26
FR17C1044I2 (fr) 2018-12-07
ES2593360T3 (es) 2016-12-07
EP2348035A3 (en) 2011-09-14
ES2603532T3 (es) 2017-02-28
US9757444B2 (en) 2017-09-12
EP2348034A2 (en) 2011-07-27
EP2348034B1 (en) 2016-11-02
BE2017C056I2 (OSRAM) 2022-02-01
EP1442047A2 (en) 2004-08-04
PT2371838E (pt) 2016-03-23
PT2341062T (pt) 2017-06-02
US20110076299A1 (en) 2011-03-31
NL300897I1 (nl) 2017-10-20
EP3199539A1 (en) 2017-08-02
JP5404441B2 (ja) 2014-01-29
EP2371836B1 (en) 2016-12-14
US11116829B2 (en) 2021-09-14
PT2371836T (pt) 2017-02-17
CA2939781C (en) 2022-09-13
AU2009213040C1 (en) 2012-10-11
BR0212999A (pt) 2006-05-23
EP2348034A3 (en) 2011-09-21
EP1442047A4 (en) 2005-06-01
EP2341062B1 (en) 2017-03-29
US9623101B2 (en) 2017-04-18
AU2012202916A1 (en) 2012-06-07
US8563006B2 (en) 2013-10-22
EP2343308A3 (en) 2011-07-27
LUC00042I2 (OSRAM) 2017-12-20
FR17C1042I2 (fr) 2018-12-07
EP2332961A2 (en) 2011-06-15
JP2016165275A (ja) 2016-09-15
LUC00041I2 (OSRAM) 2017-12-20
PT2343308E (pt) 2015-03-25
LUC00041I1 (OSRAM) 2017-10-16
NL300896I1 (nl) 2017-10-20
BE2017C057I2 (OSRAM) 2022-02-01
CA2894296A1 (en) 2003-08-07
EP2341063A2 (en) 2011-07-06
JP2015214545A (ja) 2015-12-03
EP2343308B1 (en) 2015-02-18
EP2366707A1 (en) 2011-09-21
ES2609039T3 (es) 2017-04-18
JP2010162023A (ja) 2010-07-29
EP2371838A1 (en) 2011-10-05
DK2341062T3 (en) 2017-05-08
PT2348035E (pt) 2015-03-25
ES2549764T3 (es) 2015-11-02
LU92786I2 (fr) 2015-11-02
FR17C1043I2 (fr) 2018-12-07
ES2532640T3 (es) 2015-03-30
IL161052A0 (en) 2004-08-31
MXPA04003356A (es) 2004-11-29
PT2341063E (pt) 2015-10-29
KR20100121699A (ko) 2010-11-18
EP2341062A3 (en) 2011-09-14
EP2341063B1 (en) 2015-08-26
US20120294880A1 (en) 2012-11-22
US20060257413A1 (en) 2006-11-16
US20150216960A1 (en) 2015-08-06
EP2351767A3 (en) 2011-09-14
BE2017C055I2 (OSRAM) 2022-02-01
FR17C1044I1 (OSRAM) 2017-12-22
LUC00040I2 (OSRAM) 2017-12-20
IL161052A (en) 2015-04-30
DK2348036T3 (en) 2016-02-22
PT2351767E (pt) 2015-10-30
AU2018203627A1 (en) 2018-06-07
DK2351767T3 (en) 2015-10-26
AU2009213040B2 (en) 2012-03-01
JP2014012002A (ja) 2014-01-23
PT2332961T (pt) 2016-09-28
WO2003063766A3 (en) 2004-01-08
EP2348035A2 (en) 2011-07-27
ES2625876T3 (es) 2017-07-20
EP1442047B1 (en) 2016-03-16
EP2371838B1 (en) 2015-12-16
US9168293B2 (en) 2015-10-27
MX349481B (es) 2017-07-31
EP3199539B1 (en) 2020-03-11
US8101194B2 (en) 2012-01-24
DK2348035T3 (en) 2015-04-20
ES2615206T3 (es) 2017-06-05
CN1578785A (zh) 2005-02-09

Similar Documents

Publication Publication Date Title
ES2603531T3 (es) Nuevas composiciones inmunogénicas para la prevención y tratamiento de enfermedad meningocócica
Masignani et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870
DK175788B1 (da) Vaccine imod meningococcussygdomme, deri indgående komponenter, disses anvendelse og rekombinanter, som eksprimerer dem
Ala'Aldeen et al. Immune responses in humans and animals to meningococcal transferrin-binding proteins: implications for vaccine design
EP0462210B1 (en) Vaccines for nontypable haemophilus influenzae
JP2006525330A (ja) 髄膜炎菌性疾患の予防および処置のための新規免疫原性組成物
CN102580072A (zh) 组合式奈瑟球菌组合物
ES2270523T3 (es) Antigenos de superficie y proteinas utiles en composiciones para la diagnosis y prevencion de la enfermedad de lyme.
Bergström et al. Molecular and cellular biology of Borrelia burgdorferi sensu lato.
AU744733B2 (en) Neisseria lactoferrin binding protein
CN100593544C (zh) 酶活性减少的非典型流感嗜血杆菌的p4蛋白突变体
US6391313B1 (en) Multi-component vaccine to protect against disease caused by Haemophilus influenzae and Moraxella catarrhalis
US6335182B1 (en) Recombinant Haemophilus influenzae adhesin proteins
CN101448522A (zh) 包含蛋白质nmb0938的药物组合物
EP1535928B1 (en) Vaccine compositions comprising Omp85 proteins of Neisseria gonorrhoeae and Neisseria meningitidis
CN101443037A (zh) 包含蛋白质nma0939的药物组合物
MXPA99011210A (es) Genes receptores de lactoferrina de moraxella
CZ2000530A3 (cs) Protein Neisserie vázající laktoferin